S&P 500   4,693.26 (+0.14%)
DOW   35,692.18 (-0.08%)
QQQ   398.29 (+0.12%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,693.26 (+0.14%)
DOW   35,692.18 (-0.08%)
QQQ   398.29 (+0.12%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,693.26 (+0.14%)
DOW   35,692.18 (-0.08%)
QQQ   398.29 (+0.12%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,693.26 (+0.14%)
DOW   35,692.18 (-0.08%)
QQQ   398.29 (+0.12%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)

Global stocks mixed after Fed says ready to act on inflation

Thursday, November 25, 2021 | Joe Mcdonald, AP Business Writer


A currency trader watches monitors at the foreign exchange dealing room of the KEB Hana Bank headquarters in Seoul, South Korea, Thursday, Nov. 25, 2021. Asian stock markets fell Thursday after Federal Reserve officials indicated they were ready to raise interest rates sooner than expected if needed to cool inflation.(AP Photo/Ahn Young-joon)

BEIJING (AP) — Global stock markets mostly rose Thursday after Federal Reserve officials indicated they were ready to hike interest rates sooner than expected if needed to cool U.S. inflation.

London, Tokyo, Frankfurt and Hong Kong markets advanced, while Shanghai declined.

Wall Street futures were higher. U.S. markets were closed for the Thanksgiving holiday. They reopen Friday for a shortened trading session.

Fed officials at their October policy meeting said they “would not hesitate” to respond to inflation, according to notes released Wednesday. They foresaw the possibility of raising rates “sooner than participants currently anticipated.”

That fueled investor fears the Fed and other central banks might feel pressure to withdraw economic stimulus that has been boosting stock prices. Fed officials earlier indicated they might raise rates late next year.

Higher prices combined with stronger U.S. hiring suggest the attitude at the next Fed meeting might be “unabashedly more hawkish,” said Tan Boon Heng of Mizuho Bank in a report.

In early trading, the FTSE in London rose less than 0.1% to 7,289.90 and the DAX in Frankfurt gained 0.3% to 15,927.78. The CAC 40 in Paris added 0.3% to 7,063.84.

Futures for the S&P 500 and the Dow Jones Industrial Average were up 0.3%.

In Asia, the Shanghai Composite Index lost 0.2% to 3,584.18 while the Nikkei 225 in Tokyo gained 0.7% to 29,499.28. The Hang Seng in Hong Kong advanced 0.2% to 24,740.16.

The Kospi in Seoul lost 0.5% to 2,980.27 after the Korean central bank raised its policy interest rate by 0.25 percentage points to 1% in line with expectations.

Sydney's S&P-ASX 200 added 0.1% to 7,407.30 and India's Sensex gained 0.8% to 58,811.46. New Zealand and Jakarta advanced while Singapore and Bangkok declined.

On Wall Street, the S&P 500 advanced 0.2%. Gains in technology, real estate and energy stocks outweighed a slide in banks and materials companies.

The Dow slipped less than 0.1% while the Nasdaq composite gained 0.4%.

The Fed notes showed officials still believe this year's inflation spike is likely to be temporary but acknowledged prices rose more than expected.

The notes covered the October meeting at which Fed board members voted to take the first steps to roll back easy credit and other measures to support an economic recovery from the coronavirus pandemic.

A wide range of industries have been hit by inflation pressures and disruptions in supplies of raw materials and components. Forecasters worry consumers might cut spending if retail prices keep rising.

Consumer spending rose 1.3% in October, slightly more than double the previous month's rise, according to the U.S. Commerce Department.

The Labor Department reported the number of Americans applying for unemployment benefits fell last week to its lowest level in more than half a century.

In energy markets, benchmark U.S. crude lost 5 cents to $78.34 per barrel in electronic trading on the New York Mercantile Exchange. Brent crude, used to price international oils, gained 10 cents to $81.15 per barrel in London.

The dollar fell to 115.36 yen from 115.48 yen. The euro advanced to $1.1221 from $1.1199.


7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that are ready to make strong moves forward in 2022.

View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022".


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.